Metraipolis › archive › dc_e84f2bcba266

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive,… — Europe PMC PMID:41423595

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41423595
DOI
10.1186/s13058-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-10-08T04:30:46.908Z
SHA-256 of the archived text
d361790e1369be919dec95802bc1ab6bb619d70dd1b1fd4e0f2309f1bbcddb01
Stable URL of this page
https://metraipolis.com/documento/dc_e84f2bcba266

How to cite

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive,… — Europe PMC PMID:41423595 — Europe PMC (en), https://europepmc.org/article/MED/41423595 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e84f2bcba266 (Metraipolis archive dc_e84f2bcba266, sha256 d361790e1369be919dec95802bc1ab6bb619d70dd1b1fd4e0f2309f1bbcddb01)
BibTeX
@misc{dce84f2bcba266,
  title = {Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive,… — Europe PMC PMID:41423595},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41423595},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e84f2bcba266; sha256 d361790e1369be919dec95802bc1ab6bb619d70dd1b1fd4e0f2309f1bbcddb01},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41423595. Agents can read the archived copy with the MCP tool read_document.